How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Soft Tissue Neoplasms Market
- By Tumor Type: Benign Soft Tissue Tumors, Malignant Soft Tissue Sarcomas, Intermediate (Locally Aggressive) Tumors
- By Histological Subtype: Liposarcoma, Leiomyosarcoma, Synovial Sarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Rhabdomyosarcoma
- By Treatment Modality: Surgical Resection, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy
- By Diagnostic Method: Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Biopsy, Ultrasound Imaging, Molecular Genetic Testing
- By Patient Age Group: Pediatric, Adult, Geriatric
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Benign Soft Tissue Tumors leads By Tumor Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 301 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Soft Tissue Neoplasms Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bristol-Myers Squibb Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Merck & Co. Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Johnson & Johnson
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Amgen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Takeda Pharmaceutical Company Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →GlaxoSmithKline plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Bayer AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →AbbVie Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Seattle Genetics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Benign Soft Tissue Tumors76.2
- Malignant Soft Tissue Sarcomas14.9
- Intermediate (Locally Aggressive) Tumors8.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Pfizer Inc.16.8
- Novartis AG24.8
- Eli Lilly and Company5.1
- Bristol-Myers Squibb Company11.2
- Roche Holding AG4.9
- Merck & Co. Inc.9.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.3
- Europe21.7
- Asia Pacific21.6
- Latin America12.6
- Middle East and Africa10.8
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 81 | 81 | 92 | 92 | 96 | 94 | 89 |
| Novartis AG | 80 | 87 | 83 | 70 | 80 | 75 | 79 |
| Eli Lilly and Company | 82 | 76 | 75 | 67 | 84 | 70 | 76 |
| Bristol-Myers Squibb Company | 76 | 70 | 58 | 75 | 73 | 67 | 70 |
| Roche Holding AG | 53 | 69 | 51 | 68 | 54 | 54 | 58 |
| Merck & Co. Inc. | 67 | 67 | 58 | 62 | 63 | 63 | 63 |
| AstraZeneca plc | 59 | 41 | 57 | 46 | 59 | 51 | 52 |
| Johnson & Johnson | 35 | 57 | 59 | 46 | 45 | 45 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Pfizer Inc.
- Novartis AG
- Eli Lilly and Company
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Pfizer Inc. | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Novartis AG | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Eli Lilly and Company | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Bristol-Myers Squibb Company | ✓ | ✓ | − | ✓ | − | ◐ |
| Roche Holding AG | − | ◐ | ◐ | ◐ | − | − |
| Merck & Co. Inc. | ✓ | − | − | − | ◐ | ◐ |
| AstraZeneca plc | − | − | ◐ | − | − | − |
| Johnson & Johnson | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Tumor Type in North America, then scale across Soft Tissue Neoplasms Market — a $359M beachhead inside a $5.15B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Benign Soft Tissue Tumors
Best fit — highest urgency & budget in Tumor Type.
Malignant Soft Tissue Sarcomas
Strong fit — clear ROI and a fast path to value.
Intermediate (Locally Aggressive) Tumors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Tumor Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Histological Subtype & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Treatment Modality
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Tumor Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Soft Tissue Neoplasms Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Soft Tissue Neoplasms Market is a high-growth opportunity — $7.43B by 2033, compounding at 10.9%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.9% CAGR
Demand compounds through 2033, outpacing GDP across Tumor Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Tumor Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Histological Subtype optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Soft Tissue Neoplasms Market — a $8.61B market by 2033. Plan: grow share from 7.0% to 12.7%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.0% | 12.7% | Behind |
| Revenue | $558M | $1.09B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 31.6% | 44.2% | On track |
| Customer retention | 85.1% | 95.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Tumor Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Histological Subtype capability
A defensible second engine — invest in Histological Subtype to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Tumor Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Histological Subtype
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $147M capacity & capability investment
- Greenlight bolt-on M&A in Histological Subtype
- Authorise North America expansion plan
- Fund R&D program for Tumor Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Sales deck · value proposition
Win the Soft Tissue Neoplasms Market conversation — a $6.09B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Tumor Type
Goal Grow share in Tumor Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Soft Tissue Neoplasms Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Soft Tissue Neoplasms Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Soft Tissue Sarcoma Drug Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportSoft Touch Lamination Film Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportSoft Touch Polyester Film Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportSoft X-ray Detector Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportSoftball Equipment and Gear Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportSoftball Face Guard Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportSoftball Gloves and Mitts Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportSoftball Pitching Machine Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportSoftballs Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportSoft-boiled Eggs Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportSoftener Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportSoftgel Capsules for Supplements Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy